CD274 and non-small cell lung carcinoma: Similarly, in the IMpower 010 phase 3 trial, stage II-IIIA NSCLC patients whose tumors expressed programmed cell death-1 ligand (PD-L1), adjuvant atezolizumab (a monoclonal antibody targeting PD-L1) increased three-year disease-free survival rates to 60% compared to 48% with standard care (p = 0.0039) [26].